BR0315565A - Método para se obter uma linhagem celular de mamìfero adaptada para crescer em meio livre de soro e proteìna, linhagem celular de mamìfero, uso do método, anticorpos humanizados contra o receptor de egf hr3 ou seus fragmentos, contra o antìgeno cd6 t1ht ou seus fragmentos, e contra o antìgeno cd3 t3q ou seus fragmentos - Google Patents
Método para se obter uma linhagem celular de mamìfero adaptada para crescer em meio livre de soro e proteìna, linhagem celular de mamìfero, uso do método, anticorpos humanizados contra o receptor de egf hr3 ou seus fragmentos, contra o antìgeno cd6 t1ht ou seus fragmentos, e contra o antìgeno cd3 t3q ou seus fragmentosInfo
- Publication number
- BR0315565A BR0315565A BR0315565-0A BR0315565A BR0315565A BR 0315565 A BR0315565 A BR 0315565A BR 0315565 A BR0315565 A BR 0315565A BR 0315565 A BR0315565 A BR 0315565A
- Authority
- BR
- Brazil
- Prior art keywords
- fragments
- cell line
- mammalian cell
- antigen
- free medium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
"MéTODO PARA SE OBTER UMA LINHAGEM CELULAR DE MAMìFERO ADAPTADA PARA CRESCER EM MEIO LIVRE DE SORO E PROTEìNA, LINHAGEM CELULAR DE MAMìFERO, USO DO MéTODO, ANTICORPOS HUMANIZADOS CONTRA O RECEPTOR DE EGF HR3 OU SEUS FRAGMENTOS, CONTRA O ANTìGENO CD6 T1HT OU SEUS FRAGMENTOS, E CONTRA O ANTìGENO CD3 T3Q OU SEUS FRAGMENTOS". A presente invenção diz respeito a um método de obtenção de células de mamífero adaptadas a crescer em meio livre de soro e de proteínas, o qual inclui um processo em duas etapas de adaptação em que existe um intervalo crítico de concentração de proteína em que as células devem adquirir a capacidade de sobreviver em meio livre de proteínas. O intervalo crítico da concentração da proteína é especifico para cada linhagem celular. A presente invenção também diz respeito a linhagens celulares de mamíferos que crescem de uma maneira estável em um meio livre de soro e proteínas por pelo menos 40 gerações. A invenção ainda diz respeito a clones que expressam os anticorpos humanizados anti-receptores de EGF hR~ 3~ e anti-CD6 T1hT e o anticorpo quimérico anti-CD~ 3~ T~ 3~Q, assim como os fragmentos dos referidos anticorpos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU239/2002 | 2002-10-23 | ||
| CU20020239A CU23097A1 (es) | 2002-10-23 | 2002-10-23 | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
| PCT/CU2003/000012 WO2004038010A1 (es) | 2002-10-23 | 2003-10-22 | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0315565A true BR0315565A (pt) | 2005-08-23 |
| BRPI0315565B1 BRPI0315565B1 (pt) | 2022-01-25 |
| BR0315565B1 BR0315565B1 (pt) | 2022-01-25 |
Family
ID=40134843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0315565A BR0315565B1 (pt) | 2002-10-23 | 2003-10-22 | Método para se obter uma linhagem celular de mieloma nso que contém uma sequência que codifica um polipeptídeo recombinante ou uma proteína recombinante adaptada para crescer em meio livre de soro e proteína, e, uso do método |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20060036082A1 (pt) |
| EP (2) | EP2363418B1 (pt) |
| JP (1) | JP4674087B2 (pt) |
| KR (1) | KR101186048B1 (pt) |
| CN (1) | CN1714147B (pt) |
| AR (1) | AR041645A1 (pt) |
| AT (1) | ATE502103T1 (pt) |
| AU (1) | AU2003273727B2 (pt) |
| BR (1) | BR0315565B1 (pt) |
| CA (1) | CA2503315C (pt) |
| CU (1) | CU23097A1 (pt) |
| DE (1) | DE60336415D1 (pt) |
| DK (1) | DK1564285T3 (pt) |
| EA (1) | EA007465B1 (pt) |
| EC (1) | ECSP055740A (pt) |
| ES (2) | ES2624279T3 (pt) |
| GE (1) | GEP20084444B (pt) |
| HR (1) | HRP20050760A2 (pt) |
| LT (1) | LT5354B (pt) |
| LV (1) | LV13361B (pt) |
| MY (1) | MY144088A (pt) |
| NZ (1) | NZ540171A (pt) |
| PE (1) | PE20040552A1 (pt) |
| PT (1) | PT1564285E (pt) |
| TN (1) | TNSN05116A1 (pt) |
| UY (1) | UY28037A1 (pt) |
| WO (1) | WO2004038010A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104673754B (zh) * | 2015-02-14 | 2018-03-02 | 百泰生物药业有限公司 | 重组骨髓瘤细胞克隆的筛选方法及由此获得的抗体分子 |
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3694263A (en) * | 1970-10-23 | 1972-09-26 | Joseph J Korn Sr | Swimming pool cleaning methods and apparatus therefor |
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US3886616A (en) * | 1972-12-06 | 1975-06-03 | Fay A Hayes | Hand propelled swimming pool cleaner |
| US4275474A (en) * | 1979-04-30 | 1981-06-30 | Woodard Randle C | Vacuum head for swimming pool cleaning system |
| US4240174A (en) * | 1979-07-30 | 1980-12-23 | Scott Jeffrey L | Self-contained mobile pool cleaning apparatus |
| US4430214A (en) * | 1982-09-15 | 1984-02-07 | Baker Marvin E | Strainer mill for swimming pool pump intake |
| AU2986484A (en) * | 1983-06-27 | 1985-01-03 | Monash University | Leptospira strains grown in protein free medium |
| US4558479A (en) * | 1984-01-26 | 1985-12-17 | Alopex Industries, Inc. | Pool cleaner |
| US4683599A (en) * | 1984-03-30 | 1987-08-04 | Fahet Nv | Automatic pool cleaner fitting |
| US4581075A (en) * | 1985-03-15 | 1986-04-08 | Maxi-Sweep, Inc. | Self-propelled water borne pool cleaner |
| AU6291090A (en) | 1989-09-29 | 1991-04-28 | Atomic Energy Of Canada Limited | Infrared-based gas detector |
| JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
| EP0531562A1 (de) | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Kultivierung von Säugetierzellen |
| EP0784684B8 (en) * | 1994-09-16 | 2008-03-26 | Cancer Research Institute of Contra Costa | RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES |
| ATE542891T1 (de) | 1994-11-10 | 2012-02-15 | Baxter Healthcare Sa | Verfahren zur herstellung von biologischen produkten in protein-freier kultur |
| CA2211630A1 (en) | 1995-02-23 | 1996-08-29 | Quest International B.V. | Peptides for tissue and cell culture media |
| AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
-
2002
- 2002-10-23 CU CU20020239A patent/CU23097A1/es unknown
-
2003
- 2003-10-10 PE PE2003001035A patent/PE20040552A1/es not_active Application Discontinuation
- 2003-10-16 AR ARP030103776A patent/AR041645A1/es active IP Right Grant
- 2003-10-17 MY MYPI20033959A patent/MY144088A/en unknown
- 2003-10-22 DK DK03757654.3T patent/DK1564285T3/da active
- 2003-10-22 ES ES11155076.0T patent/ES2624279T3/es not_active Expired - Lifetime
- 2003-10-22 NZ NZ540171A patent/NZ540171A/en not_active IP Right Cessation
- 2003-10-22 CA CA2503315A patent/CA2503315C/en not_active Expired - Lifetime
- 2003-10-22 US US10/532,269 patent/US20060036082A1/en not_active Abandoned
- 2003-10-22 AT AT03757654T patent/ATE502103T1/de active
- 2003-10-22 ES ES03757654T patent/ES2360049T3/es not_active Expired - Lifetime
- 2003-10-22 GE GEAP20038815A patent/GEP20084444B/en unknown
- 2003-10-22 DE DE60336415T patent/DE60336415D1/de not_active Expired - Lifetime
- 2003-10-22 CN CN2003801036918A patent/CN1714147B/zh not_active Expired - Lifetime
- 2003-10-22 KR KR1020057006995A patent/KR101186048B1/ko not_active Expired - Lifetime
- 2003-10-22 EP EP11155076.0A patent/EP2363418B1/en not_active Expired - Lifetime
- 2003-10-22 AU AU2003273727A patent/AU2003273727B2/en not_active Expired
- 2003-10-22 WO PCT/CU2003/000012 patent/WO2004038010A1/es not_active Ceased
- 2003-10-22 BR BRPI0315565A patent/BR0315565B1/pt active IP Right Grant
- 2003-10-22 HR HR20050760A patent/HRP20050760A2/xx not_active Application Discontinuation
- 2003-10-22 PT PT03757654T patent/PT1564285E/pt unknown
- 2003-10-22 EP EP03757654A patent/EP1564285B1/en not_active Expired - Lifetime
- 2003-10-22 JP JP2004545689A patent/JP4674087B2/ja not_active Expired - Lifetime
- 2003-10-22 EA EA200500695A patent/EA007465B1/ru not_active IP Right Cessation
- 2003-10-23 UY UY28037A patent/UY28037A1/es not_active Application Discontinuation
-
2005
- 2005-04-22 TN TNP2005000116A patent/TNSN05116A1/en unknown
- 2005-04-22 EC EC2005005740A patent/ECSP055740A/es unknown
- 2005-05-19 LT LT2005053A patent/LT5354B/lt not_active IP Right Cessation
- 2005-05-23 LV LVP-05-61A patent/LV13361B/en unknown
-
2010
- 2010-04-13 US US12/759,208 patent/US20100197011A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Banerjee et al. | Preparation of a monoclonal antibody specific for the class IV isotype of beta-tubulin. Purification and assembly of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers from bovine brain. | |
| DE60334364D1 (de) | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern | |
| PT2305715T (pt) | Anticorpo monoclonal para a proteína de ligação a osteoprotegerina | |
| DK1232392T3 (da) | Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring | |
| CY1108545T1 (el) | Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι | |
| DE60333732D1 (de) | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen | |
| BRPI0716438A8 (pt) | Proteínas ligantes interleucina-1,3 | |
| KR910016346A (ko) | 광견병 바이러스에 대한 사람 모노클로날 항체, 이의 제조방법 및 용도 | |
| RU2017126025A (ru) | Селективное восстановление цистеиновых остатков в антителах против il-17 | |
| ATE336512T1 (de) | Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe | |
| PH12022552520A1 (en) | Antibodies binding siglec15 and uses thereof | |
| HK1049017A1 (zh) | 人受体蛋白、相关的试剂和方法 | |
| WO1999046379A3 (en) | Human receptor proteins; related reagents and methods | |
| WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
| ATE370163T1 (de) | Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen | |
| CN118772269B (zh) | 一种抗副流感病毒3型np蛋白的抗体及其应用 | |
| CN119490596B (zh) | 一种抗人IgM抗体及其应用 | |
| BR0315565B1 (pt) | Método para se obter uma linhagem celular de mieloma nso que contém uma sequência que codifica um polipeptídeo recombinante ou uma proteína recombinante adaptada para crescer em meio livre de soro e proteína, e, uso do método | |
| CN105593241B (zh) | 特异性结合her3的抗体 | |
| KR890016165A (ko) | 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도 | |
| WO2005065711A3 (en) | Mammalian receptor proteins; related reagents and methods | |
| Lee et al. | Applications of murine and humanized chimaeric monoclonal antibodies for red cell phenotyping | |
| BRPI0612184A8 (pt) | antagonista wisp-1 isolado, composição, método de inibir ou neutralizar a indução wisp-1 ou a secreção de has2 ha cd44 ou rhamm, método de tratamento de câncer anticorpos monoclonais, linhagem de células de hibridoma, anticorpo isolado anti- wisp-1, anticorpo quimérico anti-wisp-1 e antagonista ou anticorpo wisp-1 | |
| CN119039449B (zh) | 抗人IgM抗体及其制备方法和用途 | |
| CN119638830B (zh) | 针对人s100a7蛋白的抗体、抗体对和试剂盒及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 5/00 , C12P 21/08 Ipc: C12N 5/00 (2006.01), C12P 21/08 (2006.01), A61K 39 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |